NATCO Pharma Limited (IN:NATCOPHARM)
:NATCOPHARM
NATCOPHARM Stock Chart & Stats
₹893.35
-₹7.80(-0.59%)
At close: 4:00 PM EST
₹893.35
-₹7.80(-0.59%)
Day’s Range― - ―
52-Week Range₹752.10 - ₹1,134.90
Previous CloseN/A
Volume335.92K
Average Volume (3M)59.22K
Market Cap
₹197.72B
Enterprise Value₹199.35B
Total Cash (Recent Filing)₹40.77B
Total Debt (Recent Filing)₹2.61B
Price to Earnings (P/E)26.7
Beta1.02
Next Earnings
Jun 01, 2026EPS Estimate
15.76Next Dividend Ex-DateN/A
Dividend Yield0.57%
Share Statistics
EPS (TTM)8.46
Shares Outstanding179,109,860
10 Day Avg. Volume63,709
30 Day Avg. Volume59,218
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.90
Price to Sales (P/S)3.25
P/FCF Ratio10.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)40.12
Revenue Forecast (FY)₹31.85B
Bulls Say, Bears Say
Bulls Say
High Profitability & MarginsSustained, very high gross and operating margins indicate differentiated product mix and efficient operations typical of complex generics and specialty formulations. These margins support durable cash generation, funding for R&D, and resilience to pricing pressure, underpinning long‑term profitability.
Strong Balance Sheet & Low LeverageExtremely low leverage and a high equity ratio provide financial flexibility to fund launches, capex or M&A without stressing the capital structure. A high ROE shows efficient capital deployment, reducing refinancing risk and supporting sustained investment capacity over the medium term.
Robust Cash GenerationStrong free cash flow growth and near‑one conversion of net income to operating cash indicate high quality earnings and internal funding capability. Reliable cash generation supports reinvestment, partner programs and reduces dependence on external financing for durable growth initiatives.
Bears Say
Declining EPS TrendA materially negative EPS growth rate signals earnings volatility or one‑off impacts despite strong margins. Persistent EPS declines can erode investor returns, limit retained earnings for reinvestment, and suggest that net income drivers may be less stable than headline margin metrics imply.
Decrease In Gross Profit & Rising LiabilitiesReported reductions in gross profit alongside growing liabilities point to margin pressure and weakening balance sheet cushions. Rising liabilities can constrain flexibility and increase interest or covenant risk, making margin sustainability and capital allocation more challenging over the medium term.
Dependence On Partnered LaunchesRevenue and access to regulated markets rely materially on collaborations and licensing arrangements. This business model creates timing and execution risk: partner decisions, launch delays or sharing arrangements can make revenue lumpy and reduce control over commercialization outcomes for months ahead.
NATCO Pharma Limited News
NATCOPHARM FAQ
What was NATCO Pharma Limited’s price range in the past 12 months?
NATCO Pharma Limited lowest stock price was ₹752.10 and its highest was ₹1134.90 in the past 12 months.
What is NATCO Pharma Limited’s market cap?
NATCO Pharma Limited’s market cap is ₹197.72B.
When is NATCO Pharma Limited’s upcoming earnings report date?
NATCO Pharma Limited’s upcoming earnings report date is Jun 01, 2026 which is in 50 days.
How were NATCO Pharma Limited’s earnings last quarter?
NATCO Pharma Limited released its earnings results on Feb 12, 2026. The company reported ₹8.46 earnings per share for the quarter, beating the consensus estimate of ₹5.267 by ₹3.193.
Is NATCO Pharma Limited overvalued?
According to Wall Street analysts NATCO Pharma Limited’s price is currently Overvalued.
Does NATCO Pharma Limited pay dividends?
NATCO Pharma Limited pays a Quarterly dividend of ₹1.5 which represents an annual dividend yield of 0.57%. See more information on NATCO Pharma Limited dividends here
What is NATCO Pharma Limited’s EPS estimate?
NATCO Pharma Limited’s EPS estimate is 15.76.
How many shares outstanding does NATCO Pharma Limited have?
NATCO Pharma Limited has 179,109,860 shares outstanding.
What happened to NATCO Pharma Limited’s price movement after its last earnings report?
NATCO Pharma Limited reported an EPS of ₹8.46 in its last earnings report, beating expectations of ₹5.267. Following the earnings report the stock price went down -1.275%.
Which hedge fund is a major shareholder of NATCO Pharma Limited?
Currently, no hedge funds are holding shares in IN:NATCOPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NATCO Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Technical Analysis
Glenmark Pharmaceuticals Limited
―
―
Jubilant Pharmova Limited
―
Marksans Pharma Limited
―
Rainbow Childrens Medicare Limited
―